Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Correction *

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 23, 2022 11:44am

122 Views

Post# 34454006

RE:Correction *

Duster340 wrote: up 4 cents on 13.94k volume

And that's the ticket - waiting for volume to come back.
When does it come back ?
On good news.

It seems there's potential for lots of good news in 2022 - just waiting for it !!!!

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December